Klotho’s role in some patients with Alzheimer’s disease revealed?

Last Updated on

April 24, 2020 – The klotho gene is named after the fanciful Greek goddess of destiny Clotho who turns the string of life known to be related with longer life and improved cognizance. In modern biology, allelic variants of the klotho gene in fact have been associated with long life span. Klotho seems also related to a defensive capacity against psychological debilitations and Alzheimer’s disease (AD) in people conveying variants of the APOE4 gene that predispose individuals to a higher risk for the development of AD, a recent study from Stanford University, published online April 13 in JAMA. Neurology, has found.

Individuals who are heterozygous (i.e., they are carrying one copy out of two) for a particular klotho allelic variant known as klotho-VS, estimated to be about 25% of the population, produce increased serum levels of the klotho protein, which is associated with protective effects on healthy aging and longevity compared with those with no or two (i.e., being homozygous for this variant) klotho-VS alleles. Previous observational studies indicated that patients carrying certain forms of the APOE4 gene were at heightened genetic susceptibility for development of dementia along with heightened susceptibility  to the detrimental effects of various lifestyle-related risk factors, mostly because of varying degrees of amyloid bild-up in the brain (i.e., cerebrum). As recently as 2019 it was found that people carrying the APOE4 gene who had a heterozygous klotho-VS status had less amyloid in the cerebrum.

These observations led to the questions if patients with a heterozygous klotho-VS status could be protected from developing neurodegenerative diseases, such as AD, for example, and whether patients who are known to carr the APOE4 gene could be candidates for remedy of their future danger of development of AD by boosting pathways identified to dependent of klotho.

In an attempt to answer at least some of the aspects of these questions, the authors of the present study investigated 25 datasets of people with hereditary data accessible on the APOE4 and klotho genotypes. Thus, the researchers analyzed these independent datasets from case-control, family-based, and longitudinal Alzheimer’s cohorts. The risk of developing mild cognitive impairment or Alzheimer’s was evaluated through competing risks regression under a case-control design. Associations with beta-amyloid, measured from cerebrospinal fluid (CSF) or brain positron emission tomography (PET), were evaluated using linear regression and mixed-effects modeling.

Participants were men and women aged 60 years and older who were non-Hispanic and of Northwestern European ancestry and had been diagnosed as being cognitively normal or having mild cognitive impairment or Alzheimer’s. The sample included 20,928 participants in case-control studies, 3008 in conversion studies, 556 in beta-amyloid CSF regression analyses, and 251 in PET regression analyses. Results showed that individuals who were heterozygous for the klotho-VS gene had a reduced risk for Alzheimer’s in those carrying APOE4 (odds ratio [OR], 0.75; 95% confidence interval [CI], 0.67 – 0.84) among the whole population aged over 60 years. This was more prominent in those aged 60 to 80 years (OR, 0.69; 95% CI, 0.61 – 0.79). In addition, control participants carrying APOE4 with klotho-VS heterozygosity were at reduced risk of converting to mild cognitive impairment or Alzheimer’s (hazard ratio, 0.64; 95% CI, 0.44 – 0.94). Further, in control participants who carried APOE4 and were aged 60 to 80 years, klotho-VS heterozygosity was associated with higher beta-amyloid in CSF (correlating to lower levels in the brain) and lower beta-amyloid on PET scans.

In contrast, however, klotho-VS status had no association with outcome in individuals who did not carry APOE4 .

The outcomes of this research are intriguing and propose new pathways for Alzheimer’s exploration. For the moment, these outcomes will help with guiding individuals who are known to carry  the APOE4 gene in therapeutic approaches. The research also opens new questions as to why a few people with the APOE4 gene never develop AD and whether heterozygosity in klotho-VS status could be the crucial determent in these clinical phenotype.

See a short sequence on some molecular events around amyloid in AD-affected brains which may be influenced by klotho-VS status:

Print Friendly, PDF & Email

 

 

Tags: , , , , , , , ,
About the Author
Joseph Gut - thasso Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.

Your opinion

Comment

@peepso_user_32129(Geetha) It seems to be an interesting post. My father is suffering from Alzheimer’s disease for nearly ten years. I came to know about popular neurologist in Chennai through the site https://www.drgbalamurali.com/. The study mentioned above offers some interesting results.
preview thumbnail
Dr.G.Balamurali, Senior Spine Consultant & Best Neurology Specialist in Chennai. Internationally Trained Neuro Specialist With 15 Years Experience In UK.
3 months ago 3 months ago

thasso: conditions

thasso: newest tweets

thasso: recent comments

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Newly discovered mutation could point to heart disease therapeutic target August 7, 2020
    New work led by Carnegie's Meredith Wilson and Steve Farber identifies a potential therapeutic target for clogged arteries and other health risks that stem from an excess of harmful fats in the bloodstream. Their findings are published by PLOS Genetics.
  • Genetic cause of congenital malformation discovered August 7, 2020
    Spontaneous mutations of a single gene are likely to cause serious developmental disorders of the excretory organs and genitalia. This is shown in an international study led by the University of Bonn and published in the journal Frontiers in Cell and Developmental Biology. The researchers also owe their findings to an unusual model organism: the […]
  • Novel approach reduces SCA1 symptoms in animal model August 7, 2020
    Research has shown that a mutation in the ATAXIN-1 gene leads to accumulation of Ataxin-1 (ATXN1) protein in brain cells and is the root cause of a rare genetic neurodegenerative disease known as spinocerebellar ataxia type 1 (SCA1). How healthy cells maintain a precise level of ATXN1 has remained a mystery, but now a study […]
  • Alport Syndrome: Research highlights link between genotype and treatment effectiveness August 7, 2020
    A large-scale analysis of the clinical characteristics of Alport syndrome in Japanese patients has revealed that the effectiveness of existing treatment with ACE inhibitors and/or angiotensin receptor blockers (RAS inhibitors) varies depending on the type of mutation in the syndrome's causal gene (COL4A5). RAS inhibitors are widely administered to patients with chronic kidney diseases as […]
  • Tasmanian devil research offers new insights for tackling cancer in humans August 6, 2020
    A rare, transmissible tumor has brought the iconic Tasmanian devil to the brink of extinction, but new research by scientists at Washington State University and the Fred Hutchinson Cancer Research Center in Seattle indicates hope for the animals' survival and possibly new treatment for human cancers.
  • checkmate 743 shows that dual immunotherapy, nivolumab + ipilimumab August 8, 2020
    The combination of first-line nivolumab and ipilimumab demonstrated an improvement of overall survival for patients with unresectable malignant pleural mesothelioma compared to platinum-based chemotherapy, according to research presented today at the International Association for the Study of Lung Cancer Virtual Presidential Symposium.
  • Phase 3 eXalt3 study shows significantly longer progression-free survival August 8, 2020
    Patients with non-small cell lung cancer (NSCLC) carrying anaplastic lymphoma kinase (ALK) gene alterations who received ensartinib experienced substantially longer progression-free survival than a matched group of patients who received crizotinib.
  • Addition of sintilimab to pemetrexed and platinum improved progression-free survival August 8, 2020
    The interim analysis of ORIENT-11, a phase III double-blind randomized trial has shown a nearly two-fold increase in progression-free survival with addition of sintilimab to chemotherapy in patients with advanced or metastatic non-squamous non-small cell lung cancer without EGFR or ALK genomic aberrations, according to research data presented today at the International Association for the […]
  • Heart attack case rates, treatment approaches, outcomes during COVID-19 pandemic August 7, 2020
    The increases and decreases in patient volume and associated changes in treatment experienced by individuals presenting with acute heart attack (myocardial infarction) before and immediately after the onset of the COVID-19 pandemic are examined in this observational study.
  • COVID recovery choices shape future climate August 7, 2020
    A new international study, led by the University of Leeds, warns that even with some lockdown measures staying in place to the end of 2021, without more structural interventions global temperatures will only be roughly 0.01°C lower than expected by 2030. However, the study estimates that including climate policy measures as part of an economic […]
Top